Molecule developed that helps target T-cells to fight brain cancer

T-Cell immunotherapy is a multi-billion dollar success. Companies are genetically engineering an individual’s own immune cells to attack cancer in the blood or lymph system. Chimeric antigen receptor T-cell therapy, or CAR-T therapy has seen huge acquisitions and investments. Gilead Sciences paid $11.9 billion for Kite Pharma, which received FDA approval for its own CAR-T …

Read more

Hundreds of modifications to engineered cells against cancer and other diseases to make it more effective and lower costs

CAR-T cell therapy refers to a treatment that uses transformed cells for cancer therapy. T-cells can be removed from a person, genetically altered and put them back into the patient for them to attack the cancer cells. Killer T-Cells have been used and modified to identify cancer cells which enables the T-Cells to kill cancer …

Read more